secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACHIEVE LIFE SCIENCES, INC. (ACHV)
CIK:        0000949858
Form:       8-K
Filed at:   2024-12-09T23:59:59+00:00
Accession:  0000950170-24-134558
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Achieve Life Sciences appoints Mark K. Oki as CFO effective December 5, 2024
----------------------------------------------------------------------------

- Mark Oki previously CFO of Aytu Biopharma, Vivus LLC, Alexza Pharmaceuticals.
- Base salary $450,000/year; annual discretionary bonus up to 40% of base.
- Awarded option for 72,000 shares (1/3 vest year 1, then monthly) and 168,000 performance-based RSUs.
- Severance: 12 months salary (24 months on change in control) plus healthcare and accelerated equity vesting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/949858/000095017024134558/0000950170-24-134558-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/949858/000095017024134558/achv-20241205.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-134558

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer